Literature DB >> 15182263

Management of malignant pleural effusions.

Y C Gary Lee1, Richard W Light.   

Abstract

Malignant pleural effusion is a common clinical problem. Evacuation of the pleural fluid and prevention of its reaccumulation are the main aims of management. Pleurodesis should be attempted early, although considerable practice variations exist in the way it is performed. There is a lack of consensus among respiratory physicians worldwide on the optimal method and agent for pleurodesis. Talc remains the most commonly used pleurodesing compound in most countries. While talc produces a higher success rate than other compounds, it generates more side-effects. The association between talc and ARDS continues to be debated. Ambulatory small-bore pleural catheter drainage followed by intrapleural instillation of a pleurodesing agent is increasingly accepted as an alternative to conventional in-patient pleurodesis. Development of novel methods to control pleural fluid formation should be made a high priority in future pleural research.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182263     DOI: 10.1111/j.1440-1843.2004.00566.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  26 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery.

Authors:  Pei-Jun Liu; Chi-De Chen; Chih-Liang Wang; Yi-Cheng Wu; Chia-Wei Hsu; Chien-Wei Lee; Lien-Hung Huang; Jau-Song Yu; Yu-Sun Chang; Chih-Ching Wu; Chia-Jung Yu
Journal:  Mol Cell Proteomics       Date:  2015-01-31       Impact factor: 5.911

3.  Asymptomatic malignant pleural effusion: to observe or to manage.

Authors:  Sevak Keshishyan; Kassem Harris
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

4.  Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.

Authors:  Hanbo Le; Xiaoling Wang; Yao Zha; Jie Wang; Wangyu Zhu; Zhinan Ye; Xiaoguang Liu; Haijie Ma; Yongkui Zhang
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

Review 5.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

6.  Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice.

Authors:  Yunfen Wang; Yanwen Yao; Hongbin Liu; Xingqun Ma; Tangfeng Lv; Dongmei Yuan; Xinwu Xiao; Jie Yin; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2015-02

7.  Bleomycin in the treatment of 50 cases with malignant pleural effusion.

Authors:  Novin Nikbakhsh; Ali Pourhasan Amiri; Danial Hoseinzadeh
Journal:  Caspian J Intern Med       Date:  2011

Review 8.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

Review 9.  Malignant pleural effusion and algorithm management.

Authors:  Konstantinos Zarogoulidis; Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Nikolaos Machairiotis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Eirini Terzi; Bojan Zaric; Haidong Huang; Lutz Freitag; Dionysios Spyratos
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

10.  Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(®) Injection) for Malignant Pleural Effusion.

Authors:  Jeong Su Cho; Kook Joo Na; Yongjik Lee; Yeong Dae Kim; Hyo Yeong Ahn; Chang Ryul Park; Young Chul Kim
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-12-04       Impact factor: 1.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.